Impact of biosimilars in psoriasis treatment;Impacto dos biossimilares no tratamento da psoríase

Acta Medica Portuguesa

Volumn 26, Issue 6, 2013, Pages 646-648

  Torres, Tiago ^a,b   Filipe, Paulo ^c,d   Selores, Manuela ^a,b  

^a Institute of Biomedical Sciences Abel Salazar   (Portugal)

^b UNIVERSITY OF PORTO   (Portugal)

^c Centro Hospitalar Lisboa Norte   (Portugal)

^d UNIVERSITY OF LISBON   (Portugal)

Author keywords

Biological Agents; Biosimilar Pharmaceuticals; Portugal; Psoriasis drug therapy

Indexed keywords

ADALIMUMAB; BIOSIMILAR AGENT; ETANERCEPT; INFLIXIMAB; USTEKINUMAB;

ANKYLOSING SPONDYLITIS; BIOAVAILABILITY; BIOEQUIVALENCE; BIOLOGICAL THERAPY; DRUG EFFICACY; DRUG SAFETY; HUMAN; IMMUNOGENICITY; NOTE; PATENT; PATIENT SAFETY; PSORIASIS; PSORIATIC ARTHRITIS;

BIOSIMILAR PHARMACEUTICALS; HUMANS; PSORIASIS;

EID: 84891543809     PISSN: 0870399X     EISSN: 16460758     Source Type: Journal    
DOI: None     Document Type: Note

References (10)

1. Gudjonsson JE, Elder JT. Psoriasis: epidemiology. Clin Dermatol. 2007;25:535-46.
2. Torres T, Velho GC, Sanches M, Selores M. Psoríase na era dos biológicos. Acta Med Port. 2010;23:493-8.
3. European Medicines Agency. Questions and answers on biosimilar medicines (similar biological medicinal products). London: EMA; 2012.
4. European Medicines Agency. Guideline on similar biological medicinal products. London: EMA; 2005.
5. WHO Expert Committee on Biological Standardization. Guidelines on Evaluation of Similar Biotherapeutic Products (SBPs). Geneve: WHO; 2010.
6. Abraham I, Sun D, Bagalagel A, Altyar A, Mohammed A, Tharmarajah S, et al. Biosimilars in 3D: definition, development and differentiation. Bioengineered. 2013;4:203-6.
7. European Medicines Agency. Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substances: quality issues. 2012 18 January 2013.
8. Schellekens H. Immunologic mechanisms of EPO-associated pure red cell aplasia. Best Pract Res Clin Haematol. 2005;18:473-80.
9. European Medicines Agency. European Medicines Agency recommends approval of first two monoclonal-antibody biosimilars. London: EMA; 2013.
10. Guideline on similar biological medicinal products containing monoclonal antibodies-non-clinical and clinical issues. EMA/CHMP/ BMWP/403543/2010. London: EMA; 2012.